Author's response to reviews

Title: Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE)

Authors:

Ahmed K Moaweih (dr.ahmedmotaweih.cardio@yahoo.com)
Elena Usova (usovaelena@mail.ru)
Wajid Hussain (wajiddr87@yahoo.com)
Ziad Dello (ha61@hotmail.com)
Birgit Schmidt (birgit.schmidt1@bayer.com)
Thomas Petri (thomas.petri@bayer.com)

Version: 4 Date: 16 February 2015

Author's response to reviews: see over
To: The Editorial Board  
BMC Cardiovascular Disorders

16 February 2015

Dear Sir or madam

**Manuscript ID:** 1357637081143185

**Title:** Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE)

Thank you accepting our manuscript in principle. We are pleased to send you a point-by-point response to the final editor’s remarks and a resubmitted manuscript with the amendments highlighted in the correction mode.

We confirm that the files have been formatted according to the journal style.

Please let us know if you have any additional comments or require any additional amendments. We look forward to the journal decision on our revised manuscript version.

Yours faithfully

Thomas Petri, PhD
Medical Advisor, Bayer HealthCare Pharmaceuticals
Muellerstr. 178, S102, 6.OG, R.172
13353 Berlin, Germany
### Additional Requests

<table>
<thead>
<tr>
<th>Request #1</th>
<th>Author response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give the specific names and affiliations of the ethics committees that approved the study in Bahrain, Egypt, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. For independent ethic committees please describe by what authority they are able to grant ethical approval, together with appropriate references and/or links. Add this information to the Methods section.</td>
<td>After rechecking with the medically responsible colleague for Bahrain, Egypt, Oman, Qatar, Saudi Arabia, and the United Arab Emirates it turned out that no EC approval was required for this study at the time of the study conduct, just as it was already described for Lebanon and Jordan. The manuscript was amended accordingly.</td>
</tr>
<tr>
<td><strong>Request #2</strong></td>
<td><strong>Author response</strong></td>
</tr>
<tr>
<td>Declare the Bayer Pharma funding for the study in the Competing Interests section, in addition to the Acknowledgements section. Please note that this is a standard requirement and does not imply any malpractice on your part.</td>
<td>The study activities funded by Bayer were additionally listed now also in the “Competing interests” section.</td>
</tr>
</tbody>
</table>